三生制药
3SBIO INC.

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1530)

VOLUNTARY ANNOUNCEMENT
3SBio's rESP injection has completed the enrolment of subjects for phase II clinical study

3SBio Inc. (the "**Company**") wishes to provide to the shareholders of the Company the attached press release in respect of the "study of using intravenous injection of recombinant erythropoietin stimulating protein injection (CHO cell) to maintain the treatment of patients that suffer from chronic kidney disease and anemia after hemodialysis (multi-centered, randomized, open, positive drug parallel-controlled phase II clinical study)" of the Company's self-developed recombinant and long-acting erythropoietin stimulating protein (rESP) injection (research code: SSS06) has recently completed the required enrolment of subjects.

This is a voluntary announcement made by the Company. The Company cannot guarantee that it is able to successfully develop or eventually launch SSS06. Shareholders of the Company and potential investors are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
3SBio Inc.
Dr. LOU Jing
Chairman

Shenyang, the PRC
23 February 2021

As at the date of this announcement, the directors of the Company are Dr. LOU Jing and Ms. SU Dongmei as executive directors; Mr. HUANG Bin and Mr. TANG Ke as non-executive directors; and Mr. PU Tianruo, Mr. David Ross PARKINSON and Dr. WONG Lap Yan as independent non-executive directors.

三生制药
3SBIO INC.

Press release

3SBio's rESP injection has completed the enrolment of subjects for phase II clinical study

(SHANGHAI, China, February 23, 2021) Chinese leading biopharmaceutical company, 3SBio Inc. (01530.HK) ("**3SBio**" or "**Company**"), announced today that the "study of using intravenous injection of recombinant erythropoietin stimulating protein injection (CHO cell) to maintain the treatment of patients that suffer from chronic kidney disease and anemia after hemodialysis (multi-centered, randomized, open, positive drug parallel-controlled phase II clinical study)" of the Company's self-developed recombinant and long-acting erythropoietin stimulating protein (rESP) injection (research code: SSS06) has recently completed the required enrolment of subjects.

The phase II clinical trial included the SSS06 (administered once weekly) group, the SSS06 (administered once every two weeks) group and the EPIAO group (positive drug control group). There is a total of 150 subjects enrolled. The preliminary results from analyzing the acquired clinical data stated that SSS06 have longer half-life period and stability. It has also shown good safety and durability both in the administered once weekly group and the administered once every two weeks group. The subjects enrolled will continue to participate in a 24-week treatment period and a 8-week evaluation period.

Anemia is a common complication of Chronic Kidney Disease (CKD), the incidence of which gradually increases along with the decrease in kidney function. The pathogenesis of anemia is the insufficient production of endogenous EPO, which is mainly produced in kidney, as a result of the gradual damage to kidney tissue during the development of chronic kidney disease which resulted in renal anemia. When a patient with chronic kidney disease enters into phase 5, i.e. end-stage renal disease (ESRD), the incidence of anemia could be as high as 98.2%. The degree of anemia of patient with chronic kidney disease who received hemodialysis treatment would directly affect the body function, physical pain, general health, mental health and other indicators for quality of life of patients. With the increase in the degree of anemia, the indicators for quality of life of the patients would decrease, resulting in the drop of survival rate. For these patients, correction of hemoglobin level in a timely manner may significantly improve their body function, quality of life and survival rate. Recent clinical data has shown that the regular erythropoietin currently used has a short half-life period and requires frequent dosing, which caused great inconvenient to patients and medical personnel. Therefore, the development of safe, stable and efficient erythropoietin with longer in vivo elimination half-life period has become the key point of the study.

"We are glad that SSS06 has achieved new progress in clinical trial. 3SBio has always strived to explore the industry-leading biologics research sector to provide better therapeutic benefit and medication experience to patients. We will continue to speed up the clinical trial progress of this product, and expect that it would bring hope to more patients." said Dr. Jing Lou, Chairman of 3SBio.

About SSS06

SSS06 utilizes the recombinant DNA technology to conduct site-directed mutagenesis on human erythropoietin gene. The long-acting and recombinant high glycosylation protein product, which contain 165 amino acids, is produced by adding three N-linked glycosylation sites to the natural EPO sequence. The restructured rESP preserves the original biological activity while having longer stability and half-life period, which can significantly reduce the dosing frequency of patients, easy for clinical use and provide a more convenient treatment option to patients.

About 3SBio

3SBio is a leading bio-pharmaceutical company integrating research and development ("R&D"), production and sales, with a focus on improving the life quality of patients with high-quality medicines to benefit human health. At present, the Company owns more than 70 national invention patents and has launched more than 30 kinds of products into the market, covering several treatment fields, including, among others, cancer, autoimmune, kidney disease, metabolism and dermatology. The Company owns four R&D centers of the National Engineering Research Center of Antibody Medicine and dual platforms for biopharmaceutical and chemical medicine. There are 32 kinds of products under R&D, 17 kinds of them are the national new drugs. The Group also owns five production bases complying with the GMP standards. In the future, 3SBio will continue to uphold the concept of "Care for Life, Cherish Life, Create Life" to create a world-leading bio-pharmaceutical company in China. Please visit www.3sbio.com for additional information.

Cautionary Note and Forward-Looking Statements

This press release contains forward-looking statements, such as those relating to business or products' outlook, or Company's intent, plans, beliefs, expectation and strategies. These forward-looking statements are based on information currently available to the Company and are stated herein on the basis of the outlook at the time of this press release. They are based on certain expectations, assumptions and premises, some of which are subjective or beyond our control. These forward-looking statements may prove to be incorrect or may not be realized in the future. With respect to any new product or new indication, we cannot guarantee that we will be able to successfully develop or eventually launch and market such product or indication. Underlying the forward-looking statements is a large number of risks and uncertainties. Further information regarding such risks and uncertainties may be found in our other public disclosure documents. The scientific information involved may only be preliminary and empirical. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.